Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
40 studies found for:    AD02 Alzheimer's
Show Display Options
RSS Create an RSS feed from your search for:
AD02 Alzheimer's
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Biological: AFFITOPE AD02
2 Completed Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: active: AFFITOPE AD02;   Biological: control: Placebo
3 Terminated Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006
Condition: Alzheimer´s Disease
Interventions: Biological: AFFITOPE® AD02;   Biological: Placebo
4 Completed Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02
Condition: Alzheimer's Disease
Intervention: Biological: AFFITOPE AD02
5 Completed Long-term Safety and Tolerability of AFFITOPE AD02
Condition: Alzheimer's Disease
Intervention:
6 Terminated Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease
Condition: Alzheimer´s Disease
Intervention:
7 Completed Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG)
Condition: Alzheimer's Disease
Intervention:
8 Completed Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)
Condition: Alzheimer's Disease
Interventions: Biological: CAD106;   Drug: Placebo
9 Recruiting A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: AZD0530 100mg daily;   Drug: AZD0530 125mg daily;   Drug: Placebo
10 Completed Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
Condition: Alzheimer's Disease
Interventions: Drug: E2609;   Drug: Placebo for E2609
11 Completed Brain Imaging in Alzheimer's Disease
Condition: Alzheimer Disease
Intervention: Drug: [123] 5-I-A-85380
12 Completed Effect of LY2062430 on the Progression of Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: LY2062430;   Drug: Placebo
13 Active, not recruiting Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: TRx0237 150 mg/day;   Drug: TRx0237 250 mg/day;   Drug: Placebo
14 Completed
Has Results
Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: LY450139;   Drug: Placebo
15 Completed Alzheimer's Disease Treatment and Illness Perceptions Survey (TIPS) II
Condition: Alzheimer Disease
Intervention:
16 Completed Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Rosiglitazone Extended Release 2mg;   Drug: Rosiglitazone Extended Release 8mg;   Other: Placebo;   Other: Donepezil;   Other: Galantamine;   Other: Rivastigmine
17 Completed Alzheimer's Family Research
Condition: Decision Making
Intervention:
18 Active, not recruiting MAyflOwer RoAD Study: A Study of RO4602522 in Patients With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
Condition: Alzheimer Disease
Interventions: Drug: RO4601522;   Drug: RO4602522;   Drug: donepezil;   Drug: galantamine;   Drug: memantine;   Drug: placebo;   Drug: rivastigmine
19 Completed Evaluation of Age- and Alzheimer's Disease-Related Memory Disorder
Conditions: Alzheimer Disease;   Dementia;   Memory Disorder;   Healthy
Intervention:
20 Terminated
Has Results
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
Condition: Alzheimer Disease
Interventions: Drug: Bapineuzumab 0.5 mg/kg;   Drug: Bapineuzumab 1.0 m/kg

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years